Europe — EMA

Novorapid (Insulin Aspart)

Request sourcing

Pack/s

What is Insulin Aspart?

Insulin aspart, the active ingredient in Novorapid, is a rapid‑acting insulin analog presented as a solution for subcutaneous injection use. It lowers blood glucose in people with diabetes mellitus. GNH USA supplies Novorapid as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Novorapid as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

What is Insulin Aspart used for?

Novorapid is a rapid‑acting insulin that works within the carbohydrate‑digestion pathway to control post‑prandial glucose spikes.

- Type 1 diabetes mellitus: improves mealtime glucose control. - Type 2 diabetes mellitus: provides mealtime insulin coverage. - Gestational diabetes: assists in controlling post‑meal glucose levels. - Pre‑operative fasting management: helps maintain target glucose before surgery. - Diabetic ketoacidosis (DKI – DKA) adjunct: used as part of a rapid‑acting insulin regimen.

What are the side effects of Insulin Aspart?

NovNov ...

Common Side Effects: - ... - ...

What precautions apply to Insulin Aspart?

NovNov g ....

Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.

Send a sourcing enquiry for this product →